文献速递乳腺癌胸部肿瘤消化系统肿瘤

肿瘤治疗改进模式对癌症治疗期间支持性照护药物使用的影响

Impact of the Oncology Care Model on Use of Supportive Care Medications During Cancer Treatment.
PubMed 文献 · J Clin Oncol · 2022-02-25

本研究评估肿瘤治疗改进模式(OCM)对支持性照护药物合理使用的影响,纳入2013—2019年Medicare索赔数据中OCM相关化疗 episodes(n=201)与对照机构(n=534),采用双重差分法分析。结果显示OCM启动后降低了骨转移患者地舒单抗使用、中危发热性中性粒细胞减少化疗期间乳腺癌患者的预防性白细胞生长因子使用,以及高致吐风险化疗中NK1拮抗剂和长效5-羟色胺拮抗剂的预防性使用,作者认为提示更注重价值的照护。

要点

  • OCM与骨转移患者地舒单抗使用相对减少相关,如乳腺癌 episodes 相对减少5.0个百分点(90% CI,-7.1至-2.8)。
  • 中危发热性中性粒细胞减少化疗中,OCM使乳腺癌 episodes 预防性白细胞生长因子使用减少7.6个百分点(90% CI,-12.6至-2.7),肺癌和结直肠癌无影响。
  • 高或中致吐风险化疗中,OCM降低NK1拮抗剂和长效5-羟色胺拮抗剂预防性使用,如高致吐风险化疗中NK1拮抗剂减少6.0个百分点(90% CI,-9.0至-3.1)。

核心结论

  • OCM导致某些高成本支持性照护药物使用减少,提示更注重价值的照护。

研究设计与样本

  • 评估OCM相关化疗 episodes(n=201)与对照机构(n=534),使用2013—2019年Medicare索赔数据,采用双重差分法分析。

主要发现

  • OCM启动后,骨转移接受骨改良药物患者的地舒单抗使用相对减少,如乳腺癌 episodes 相对减少5.0个百分点(90% CI,-7.1至-2.8)。
  • 在高或低发热性中性粒细胞减少风险化疗中,OCM对预防性白细胞生长因子使用无影响。
  • 在中危发热性中性粒细胞减少风险化疗中,OCM使乳腺癌 episodes 预防性白细胞生长因子使用减少7.6个百分点(90% CI,-12.6至-2.7),肺癌或结直肠癌 episodes 无影响。
  • 在高或中致吐风险化疗中,OCM降低NK1拮抗剂和长效5-羟色胺拮抗剂的预防性使用,如高致吐风险化疗中NK1拮抗剂使用减少6.0个百分点(90% CI,-9.0至-3.1)。

关键数值与推荐

  • 骨转移接受骨改良药物患者的地舒单抗使用:乳腺癌 episodes 相对减少5.0个百分点(90% CI,-7.1至-2.8)。
  • 中危发热性中性粒细胞减少风险化疗:乳腺癌 episodes 预防性白细胞生长因子使用减少7.6个百分点(90% CI,-12.6至-2.7)。
  • 高致吐风险化疗:NK1拮抗剂预防性使用减少6.0个百分点(90% CI,-9.0至-3.1)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The Oncology Care Model (OCM) is an episode-based alternative payment model for cancer care that seeks to reduce Medicare spending while maintaining care quality. We evaluated the impact of OCM on appropriate use of supportive care medications during cancer treatment. METHODS: We evaluated chemotherapy episodes assigned to OCM (n = 201) and comparison practices (n = 534) using Medicare claims (2013-2019). We assessed denosumab use for beneficiaries with bone metastases from breast, lung, or prostate cancer; prophylactic WBC growth factor use for beneficiaries receiving chemotherapy for breast, lung, or colorectal cancer; and prophylactic use of neurokinin-1 (NK1) antagonists and long-acting serotonin antagonists for beneficiaries receiving chemotherapy for any cancer type. Analyses used a difference-in-difference approach. RESULTS: After its launch in 2016, OCM led to a relative reduction in the use of denosumab for beneficiaries with bone metastases receiving bone-modifying medications (eg, 5.0 percentage point relative reduction in breast cancer episodes [90% CI, -7.1 to -2.8]). There was no OCM impact on use of prophylactic WBC growth factors during chemotherapy with high or low risk for febrile neutropenia. Among beneficiaries receiving chemotherapy with intermediate febrile neutropenia risk, OCM led to a 7.6 percentage point reduction in the use of prophylactic WBC growth factors during breast cancer episodes (90% CI, -12.6 to -2.7); there was no OCM impact in lung or colorectal cancer episodes. Among beneficiaries receiving chemotherapy with high or moderate emetic risk, OCM led to reductions in the prophylactic use of NK1 antagonists and long-acting serotonin antagonists (eg, 6.0 percentage point reduction in the use of NK1 antagonists during high emetic risk chemotherapy [90% CI, -9.0 to -3.1]). CONCLUSION: OCM led to the reduced use of some high-cost supportive care medications, suggesting more value-conscious care.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Brooks GA, Landrum MB, Kapadia NS, et al. Impact of the Oncology Care Model on Use of Supportive Care Medications During Cancer Treatment. J Clin Oncol. 2022. PMID: 35213212. doi:10.1200/JCO.21.02342

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。